Literature DB >> 11119472

Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients.

K Kiuchi1, J Nejima, T Takano, M Ohta, H Hashimoto.   

Abstract

OBJECTIVE: To assess whether the concentrations of serum advanced glycation end products (AGE) in diabetic patients with obstructive coronary artery disease differ from those in type 2 diabetic patients without obstructive coronary artery disease.
DESIGN: Serum AGE concentrations were measured in type 2 diabetic patients and in non-diabetic patients, both with and without obstructive coronary artery disease, and the relation between these values and coronary disease severity was evaluated.
RESULTS: Mean (SD) serum AGE concentrations were higher (p < 0.0125) in type 2 diabetic patients with obstructive coronary artery disease (5.5 (2.5) mU/ml, n = 30) than in patients without obstructive coronary artery disease (2.8 (0. 5) mU/ml, n = 12), and higher than in non-diabetic patients with (3. 4 (1.0) mU/ml, n = 28) and without (3.2 (0.4) mU/ml, n = 13) obstructive coronary artery disease. Serum AGE was associated with the degree of coronary arteriosclerosis in type 2 diabetic patients with obstructive coronary artery disease (single vessel: n = 13, 3.4 (0.9) mU/m; two vessel: n = 6, 5.7 (1.6) mU/m; three vessel: n = 11, 7.2 (2.5) mU/ml). Serum AGE was positively correlated with serum mean four year HbA(1C) (r = 0.46, p < 0.01), but not with recent serum HbA(1C) (r = 0.24). The four groups did not differ in the other coronary risk factors.
CONCLUSIONS: Serum AGE concentrations may be associated with long term poor glycaemic control and reflect the severity of coronary arteriosclerosis in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11119472      PMCID: PMC1729572          DOI: 10.1136/heart.85.1.87

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  Production and characterization of antibodies to advanced glycation products on proteins.

Authors:  H Nakayama; S Taneda; S Kuwajima; S Aoki; Y Kuroda; K Misawa; S Nakagawa
Journal:  Biochem Biophys Res Commun       Date:  1989-07-31       Impact factor: 3.575

2.  Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum.

Authors:  W Richmond
Journal:  Clin Chem       Date:  1973-12       Impact factor: 8.327

3.  A colorimetric method for estimating serum triglycerides.

Authors:  M J Fletcher
Journal:  Clin Chim Acta       Date:  1968-11       Impact factor: 3.786

Review 4.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Authors:  M Brownlee; A Cerami; H Vlassara
Journal:  N Engl J Med       Date:  1988-05-19       Impact factor: 91.245

5.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.

Authors:  M Kirstein; J Brett; S Radoff; S Ogawa; D Stern; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

Authors:  B K Kilhovd; T J Berg; K I Birkeland; P Thorsby; K F Hanssen
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy.

Authors:  G Hasegawa; K Nakano; M Sawada; K Uno; Y Shibayama; K Ienaga; M Kondo
Journal:  Kidney Int       Date:  1991-12       Impact factor: 10.612

8.  Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure.

Authors:  L I Gidez; G J Miller; M Burstein; S Slagle; H A Eder
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

9.  Advanced glycosylation end products in patients with diabetic nephropathy.

Authors:  Z Makita; S Radoff; E J Rayfield; Z Yang; E Skolnik; V Delaney; E A Friedman; A Cerami; H Vlassara
Journal:  N Engl J Med       Date:  1991-09-19       Impact factor: 91.245

10.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

Authors:  R Bucala; K J Tracey; A Cerami
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more
  41 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

Review 3.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

4.  Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease.

Authors:  Anand Prasad; James R Lane; Sotirios Tsimikas; Ehtisham Mahmud; Srikrishna Khandrika; Peter Bekker; Manjusha Ilapakurti; Dan Nguyen; Amir Ravandi; Travis Israel
Journal:  Int J Angiol       Date:  2015-03-23

5.  Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study.

Authors:  B K Kilhovd; A Juutilainen; S Lehto; T Rönnemaa; P A Torjesen; K F Hanssen; M Laakso
Journal:  Diabetologia       Date:  2007-05-04       Impact factor: 10.122

6.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

7.  Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products.

Authors:  Ying-Ling Lai; Sae Aoyama; Ryoji Nagai; Noriyuki Miyoshi; Hiroshi Ohshima
Journal:  J Clin Biochem Nutr       Date:  2010-02-27       Impact factor: 3.114

8.  Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML).

Authors:  Marcus Baumann; Tom Richart; Daniel Sollinger; Jaroslav Pelisek; Marcel Roos; Tatiana Kouznetsova; Hans-Henning Eckstein; Uwe Heemann; Jan A Staessen
Journal:  Cardiovasc Diabetol       Date:  2009-08-06       Impact factor: 9.951

9.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

10.  Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.

Authors:  N C den Hollander; D J Mulder; R Graaff; S R Thorpe; J W Baynes; G P A Smit; A J Smit
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.